THROMBOGENICS : – Transparency Declaration
04/13/2012| 02:15pm US/Eastern
Recommend:
Regulated information
For immediate release
Transparency declaration
Leuven, Belgium - 13 April 2012 - ThromboGenics NV
(NYSE Euronext Brussels: THR), a biopharmaceutical company
focused on developing innovative ophthalmic medicines,
announces that it has received a transparency declaration
from OppenheimerFunds Inc. in accordance with the Belgian Law
of 2 May 2007 concerning disclosure of major holdings in
issuers whose shares are admitted to trading on a Belgian
regulated market.
ThromboGenics NV has received a transparency notification
from OppenheimerFunds Inc., having its registered office at
S.Tucson Way 6803, Centennial, Colorado US, indicating that,
following the acquisition of shares, its participation in the
company exceeds the 3 % threshold. Following the private
placement of March 29th, 2012, ThromboGenics has
now
35.691.432 shares outstanding. As a consequence of this
capital increase 2 shareholders have passed a threshold of
respectively 10% (L.T.Clay) and 5% (Baker Brothers) as they
did not participate in the recent capital increase.
As per 13 April 2012, based on the transparency notifications
received, ThromboGenics NV
has been informed of the following major shareholdings:
|
Shareholder
|
Number of shares
|
% of outstanding shares
|
|
Landon T Clay
|
2.576.448
|
7,21
|
|
Biggar Ltd
|
2.012.105
|
5,64
|
|
Baker Brothers
|
1.619.488
|
4,54
|
|
OppenheimerFunds Inc.
|
1.236.688
|
3,46
|
|
Clay Mathematics
|
1.099.247
|
3,07
|
- Ends -
For further information please contact:
ThromboGenics N.V., Gaston Geenslaan 1, B-3001 Leuven,
Belgium tel +32 (0)16 75 13 10 fax +32 (0)16 75 13 11
BTW/VAT BE 0881.620.924, RPR Leuven www.thrombogenics.com
About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on
developing and commercializing innovative ophthalmic
medicines. The company's lead product, ocriplasmin, has
successfully completed two Phase III clinical trials for the
pharmacological treatment of symptomatic vitreomacular
adhesion (VMA). The MAA for ocriplasmin has been accepted for
review in Europe and the BLA will be re-submitted in the U.S.
by April 2012. Ocriplasmin is in Phase II clinical
development for additional vitreoretinal conditions.
In March 2012, ThromboGenics signed a strategic partnership
with Alcon (Novartis) for the commercialization of
ocriplasmin outside the United States. Under this agreement,
ThromboGenics could receive up to a total of €375 million in
up-front and milestone payments, plus an attractive level of
royalties on Alcon's net sales of ocriplasmin. ThromboGenics
and Alcon intend to share the costs equally of developing
ocriplasmin for a number of new vireoretinal indications.
ThromboGenics is also developing two novel antibody
therapeutics in collaboration with BioInvent International.
These are TB-402 (anti-Factor VIII), a long-acting
anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase
Ib/II for cancer which has been partnered with Roche.
ThromboGenics is headquartered in Leuven, Belgium. The
Company is listed on the NYSE Euronext Brussels exchange
under the symbol THR. More information is available at www.thrombogenics.com.
ThromboGenics N.V., Gaston Geenslaan 1, B-3001 Leuven,
Belgium tel +32 (0)16 75 13 10 fax +32 (0)16 75 13 11
BTW/VAT BE 0881.620.924, RPR Leuven www.thrombogenics.com
distributed by
|
|
Recommend :
